| 000 | 01612 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250514155906.0 | ||
| 264 | 0 | _c20031030 | |
| 008 | 200310s 0 0 eng d | ||
| 022 | _a1525-4135 | ||
| 024 | 7 |
_a10.1097/00126334-200310010-00003 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBoyd, Mark A | |
| 245 | 0 | 0 |
_aPharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. _h[electronic resource] |
| 260 |
_bJournal of acquired immune deficiency syndromes (1999) _cOct 2003 |
||
| 300 |
_a134-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAcquired Immunodeficiency Syndrome _xdrug therapy |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAlkynes |
| 650 | 0 | 4 |
_aAnti-HIV Agents _xpharmacokinetics |
| 650 | 0 | 4 | _aBenzoxazines |
| 650 | 0 | 4 | _aCyclopropanes |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHIV-1 |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIndinavir _xpharmacokinetics |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aOxazines _xpharmacokinetics |
| 650 | 0 | 4 |
_aRitonavir _xpharmacokinetics |
| 700 | 1 | _aAarnoutse, Rob E | |
| 700 | 1 | _aRuxrungtham, Kiat | |
| 700 | 1 | _aStek, Michael | |
| 700 | 1 | _avan Heeswijk, Rolf P G | |
| 700 | 1 | _aLange, Joep M A | |
| 700 | 1 | _aCooper, David A | |
| 700 | 1 | _aPhanuphak, Praphan | |
| 700 | 1 | _aBurger, David M | |
| 773 | 0 |
_tJournal of acquired immune deficiency syndromes (1999) _gvol. 34 _gno. 2 _gp. 134-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00126334-200310010-00003 _zAvailable from publisher's website |
| 999 |
_c14286011 _d14286011 |
||